Innovent Biologics Stock Buy Hold or Sell Recommendation
| IVBXF Stock | USD 4.86 0.03 0.62% |
Assuming the 90 days horizon and your highly speculative risk level, our recommendation regarding Innovent Biologics is 'Strong Sell'. Macroaxis provides Innovent Biologics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IVBXF positions.
Check out Innovent Biologics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Innovent and provide practical buy, sell, or hold advice based on investors' constraints. Innovent Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
Innovent |
Execute Innovent Biologics Buy or Sell Advice
The Innovent recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Innovent Biologics. Macroaxis does not own or have any residual interests in Innovent Biologics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Innovent Biologics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Innovent Biologics Trading Alerts and Improvement Suggestions
| Innovent Biologics generated a negative expected return over the last 90 days | |
| Innovent Biologics has high historical volatility and very poor performance | |
| Innovent Biologics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.27 B. Net Loss for the year was (3.14 B) with profit before overhead, payroll, taxes, and interest of 2.98 B. | |
| Innovent Biologics has accumulated about 8.32 B in cash with (2.02 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating ... |
Innovent Biologics Returns Distribution Density
The distribution of Innovent Biologics' historical returns is an attempt to chart the uncertainty of Innovent Biologics' future price movements. The chart of the probability distribution of Innovent Biologics daily returns describes the distribution of returns around its average expected value. We use Innovent Biologics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Innovent Biologics returns is essential to provide solid investment advice for Innovent Biologics.
| Mean Return | -0.14 | Value At Risk | -7.81 | Potential Upside | 4.92 | Standard Deviation | 3.61 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Innovent Biologics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Innovent Biologics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Innovent Biologics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Innovent Biologics' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Innovent pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.17 | |
β | Beta against Dow Jones | 0.16 | |
σ | Overall volatility | 3.61 | |
Ir | Information ratio | -0.07 |
Innovent Biologics Volatility Alert
Innovent Biologics exhibits very low volatility with skewness of -0.14 and kurtosis of 5.7. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Innovent Biologics' pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Innovent Biologics' pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Innovent Biologics Fundamentals Vs Peers
Comparing Innovent Biologics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Innovent Biologics' direct or indirect competition across all of the common fundamentals between Innovent Biologics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Innovent Biologics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Innovent Biologics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Innovent Biologics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Innovent Biologics to competition |
| Fundamentals | Innovent Biologics | Peer Average |
| Return On Equity | -0.29 | -0.31 |
| Return On Asset | -0.14 | -0.14 |
| Profit Margin | (0.68) % | (1.27) % |
| Operating Margin | (0.78) % | (5.51) % |
| Current Valuation | 5.13 B | 16.62 B |
| Shares Outstanding | 1.53 B | 571.82 M |
| Shares Owned By Insiders | 7.15 % | 10.09 % |
| Shares Owned By Institutions | 44.34 % | 39.21 % |
| Price To Book | 4.22 X | 9.51 X |
| Price To Sales | 1.39 X | 11.42 X |
| Revenue | 4.27 B | 9.43 B |
| Gross Profit | 2.98 B | 27.38 B |
| EBITDA | (2.99 B) | 3.9 B |
| Net Income | (3.14 B) | 570.98 M |
| Cash And Equivalents | 8.32 B | 2.7 B |
| Cash Per Share | 5.67 X | 5.01 X |
| Total Debt | 2.02 B | 5.32 B |
| Debt To Equity | 0.29 % | 48.70 % |
| Current Ratio | 3.21 X | 2.16 X |
| Book Value Per Share | 6.54 X | 1.93 K |
| Cash Flow From Operations | (2.02 B) | 971.22 M |
| Earnings Per Share | (0.32) X | 3.12 X |
| Number Of Employees | 5.54 K | 18.84 K |
| Beta | 0.16 | -0.15 |
| Market Capitalization | 8.37 B | 19.03 B |
| Total Asset | 16.24 B | 29.47 B |
| Z Score | 2.4 | 8.72 |
| Net Asset | 16.24 B |
Innovent Biologics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Innovent . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | 9.2 T | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 4.86 | |||
| Day Typical Price | 4.86 | |||
| Price Action Indicator | 0.015 | |||
| Period Momentum Indicator | 0.03 |
About Innovent Biologics Buy or Sell Advice
When is the right time to buy or sell Innovent Biologics? Buying financial instruments such as Innovent Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Innovent Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Soft Drinks Thematic Idea Now
Soft Drinks
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.